DE2052128A1 - Antivirale Massen - Google Patents
Antivirale MassenInfo
- Publication number
- DE2052128A1 DE2052128A1 DE19702052128 DE2052128A DE2052128A1 DE 2052128 A1 DE2052128 A1 DE 2052128A1 DE 19702052128 DE19702052128 DE 19702052128 DE 2052128 A DE2052128 A DE 2052128A DE 2052128 A1 DE2052128 A1 DE 2052128A1
- Authority
- DE
- Germany
- Prior art keywords
- radical
- hasse
- atom
- imino
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000840 anti-viral effect Effects 0.000 title claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 20
- -1 imino radical Chemical class 0.000 claims description 16
- 239000007921 spray Substances 0.000 claims description 9
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 150000003254 radicals Chemical class 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 125000004434 sulfur atom Chemical group 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- HNUALPPJLMYHDK-UHFFFAOYSA-N C[CH]C Chemical compound C[CH]C HNUALPPJLMYHDK-UHFFFAOYSA-N 0.000 claims description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- QRJZGVVKGFIGLI-UHFFFAOYSA-N 2-phenylguanidine Chemical compound NC(=N)NC1=CC=CC=C1 QRJZGVVKGFIGLI-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000133 nasal decongestant Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 3
- 241000709661 Enterovirus Species 0.000 description 3
- 229940050410 gluconate Drugs 0.000 description 3
- 150000002540 isothiocyanates Chemical class 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- XTEGARKTQYYJKE-UHFFFAOYSA-M Chlorate Chemical compound [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 description 2
- 206010039105 Rhinoviral infections Diseases 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZJLRWLYVCHKHMM-UHFFFAOYSA-N (4-aminophenyl)thiourea Chemical compound NC(=S)NC1=CC=C(N)C=C1 ZJLRWLYVCHKHMM-UHFFFAOYSA-N 0.000 description 1
- HXKWSIPCTVYMBN-UHFFFAOYSA-N 2-(4-aminophenyl)guanidine Chemical compound NC(=N)NC1=CC=C(N)C=C1 HXKWSIPCTVYMBN-UHFFFAOYSA-N 0.000 description 1
- VWDSNVUXQDDXBN-UHFFFAOYSA-N 3-aminobenzenecarboximidamide Chemical compound NC(=N)C1=CC=CC(N)=C1 VWDSNVUXQDDXBN-UHFFFAOYSA-N 0.000 description 1
- WPANETAWYGDRLL-UHFFFAOYSA-N 4-aminobenzenecarboximidamide Chemical compound NC(=N)C1=CC=C(N)C=C1 WPANETAWYGDRLL-UHFFFAOYSA-N 0.000 description 1
- 101100188552 Arabidopsis thaliana OCT3 gene Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- PQWPYMAPMRQHIE-UHFFFAOYSA-N N'-(4-chlorophenyl)-4-[(N'-propan-2-ylcarbamimidoyl)amino]benzenecarboximidamide Chemical compound ClC1=CC=C(C=C1)NC(C1=CC=C(C=C1)NC(=N)NC(C)C)=N PQWPYMAPMRQHIE-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 241001233037 catfish Species 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB5226169 | 1969-10-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE2052128A1 true DE2052128A1 (de) | 1971-04-29 |
Family
ID=10463236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19702052128 Pending DE2052128A1 (de) | 1969-10-24 | 1970-10-23 | Antivirale Massen |
Country Status (6)
Country | Link |
---|---|
BE (1) | BE757955A (enrdf_load_stackoverflow) |
DE (1) | DE2052128A1 (enrdf_load_stackoverflow) |
FR (1) | FR2070160B1 (enrdf_load_stackoverflow) |
GB (1) | GB1295088A (enrdf_load_stackoverflow) |
NL (1) | NL7015457A (enrdf_load_stackoverflow) |
ZA (1) | ZA706890B (enrdf_load_stackoverflow) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX3465E (es) * | 1960-10-14 | 1980-09-12 | Wander Ltd Wander Ag Wander S | Procedimiento para la obtencion de ureas n,n'-difenil |
GB1188956A (en) * | 1967-07-14 | 1970-04-22 | Delalande Sa | N-Substituted Aromatic Amidines and process for obtaining same |
-
0
- BE BE757955D patent/BE757955A/xx unknown
-
1969
- 1969-10-24 GB GB5226169A patent/GB1295088A/en not_active Expired
-
1970
- 1970-10-09 ZA ZA706890A patent/ZA706890B/xx unknown
- 1970-10-22 NL NL7015457A patent/NL7015457A/xx unknown
- 1970-10-23 FR FR707038433A patent/FR2070160B1/fr not_active Expired
- 1970-10-23 DE DE19702052128 patent/DE2052128A1/de active Pending
Also Published As
Publication number | Publication date |
---|---|
NL7015457A (enrdf_load_stackoverflow) | 1971-04-27 |
FR2070160B1 (enrdf_load_stackoverflow) | 1974-06-21 |
BE757955A (fr) | 1971-04-23 |
GB1295088A (enrdf_load_stackoverflow) | 1972-11-01 |
FR2070160A1 (enrdf_load_stackoverflow) | 1971-09-10 |
ZA706890B (en) | 1971-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BROWN | Chronic mercurialism: A cause of the clinical syndrome of amyotrophic lateral sclerosis | |
DE1670827B2 (de) | 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-di carbmethoxy-1,4-dihydropyridin | |
DE69129331T2 (de) | Verwendung von inosittriphosphat zur zubereitung von medikamenten | |
DE3883606T2 (de) | Verwendung von Fluoxetin zur Behandlung des Diabetes. | |
EP0185210A2 (de) | Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten | |
DE60219963T2 (de) | Pharmazeutische zusammensetzung, die zur glukosekontrolle im blut von patienten mit diabetes typ 2 eingesetzt wird | |
DE2208787A1 (de) | Virusheilmittel | |
DE2824165A1 (de) | Arzneimittel mit angstneurosen und angstaehnliche neurosen beseitigender wirkung und verfahren zum zubereiten des arzneimittels | |
DE2166355C2 (de) | Verwendung von d,1-Sobrerol bei der Balsamtherapie der Atemwege | |
DE3619426A1 (de) | Mittel zur erhoehung der widerstandskraft gegen erkaeltungskrankheiten bei patienten mit eingeschraenkter lungenfunktion | |
DE2929009A1 (de) | Gegen bakterielle erkrankungen wirksame zubereitung | |
DE1917283C3 (de) | Herstellung antimikrobieller Präparate | |
DE60220825T2 (de) | Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks | |
DE3918543C2 (enrdf_load_stackoverflow) | ||
DE181050T1 (de) | 1-beta-d-ribofuranosyl-1,2,4-triazol-3-carboxamid fuer die verwendung in medizinischer behandlung von menschen. | |
DE2052128A1 (de) | Antivirale Massen | |
DE69904206T2 (de) | Verwendung von cetirizin zur vorbeugung von asthma eintritt | |
DE3232883A1 (de) | Neue salze von basischen coffein-8-aethern und ihre anwendung in pharmazeutischen praeparaten | |
DE1043587B (de) | Verfahren zur Herstellung eines Appetitzueglers | |
DE60108650T2 (de) | 1-amino-alkylcyclohexanederivate als trypanocide mittel | |
DE3520325C2 (enrdf_load_stackoverflow) | ||
DE10238161A1 (de) | Mineralstoff-Ampulle für die mucosale und topische Wirkstoffapplikation | |
DE3518559A1 (de) | Neue verwendung von dihydroergotamin | |
DE2334358A1 (de) | Pharmazeutische zubereitungen mit neuartiger wirkung | |
DE2200722A1 (de) | Virenverhindernde aromatische Verbindungen sowie Verfahren zu deren Herstellung |